1
Upstream Bio
Inflammation and Allergy
HBM contact: Dr Emil Bujak
Company status: private
Upstream Bio, a
clinical-stage biotech company advancing new therapies to treat allergy and
inflammation, is developing UPB-101, a clinical-stage monoclonal antibody that
inhibits the TSLP receptor.